Rapport Therapeutics announced the appointment of Dr. Jeffrey Sevigny as its new Chief Medical Officer, effective immediately. Dr. Sevigny brings over 15 years of leadership experience in translational and clinical drug development, with a focus on neuroscience and rare diseases. He previously served as Chief Medical Officer at Prevail Therapeutics, a subsidiary of Eli Lilly, and Senior Vice President of Neuroscience at Eli Lilly.
In his new role, Dr. Sevigny will be responsible for overseeing the development and execution of Rapport’s clinical strategy and advancing its pipeline of precision medicines. His proven ability to guide clinical programs through late-stage trials and regulatory approvals is expected to be instrumental in progressing RAP-219 and other candidates.
This executive appointment follows the stepping down of Dr. Bradley Galer as Chief Medical Officer, as previously announced in January. Dr. Sevigny's extensive background at major pharmaceutical and biotech companies, including Biogen and Novartis, is anticipated to strengthen Rapport's clinical development capabilities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.